Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial

Lung, Respiratory and Thoracic Cancer

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial

Lung Cancer

Barlesi F, Ahn JS, Solomon BJ, Nishio M, Dziadziuszko R, Lee DH, Lee JS, Zhong W, Horinouchi H, Mao W, Hochmair M, de Marinis F, Migliorino MR, Bondarenko I, Xu T, Bara I, Ding B, Ngiam C, Petric P, Wu YL

doi: 10.1016/j.lungcan.2026.109385

Lymphoma

Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patterns

Haematologica

Stuver R, Moore ZR, Barta SK, Bhansali RS, Choa R, Epstein-Peterson ZD, Ganesan N, Ghione P, Jain S, Jacobsen E, Johnson WT, Lukowski JD, Lunning M, McCabe S, Merrill M, Moskowitz AJ, Singh S, Taranto E, Yahalom J, Savage KJ, Imber BS, Horwitz SM

doi: 10.3324/haematol.2026.300853

ASH 2025

BRUIN CLL-314: Pirtobrutinib demonstrates noninferior ORR versus ibrutinib in the first head-to-head trial in BTKi-naïve patients with CLL/SLL

Lymphoma

Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial

Ann Oncol

Michot JM, Bologna S, Bastie JN, Borght TV, Brière J, Ribrag V, Bommier C, Peyrade F, Lebras L, Damaj G, Coso D, Sibon D, Bonnet C, Morschhauser F, Ghesquières H, Fruchart C, Soussain C, Becker S, Olivier P, Julian A, Molina T, Haioun C, Tilly H

doi: 10.1016/j.annonc.2025.11.006

Breast Cancer

Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database

Eur J Cancer

Aristei C, Tomatis M, Ponti A, Marotti L, Battisti NML, Leung Cheung K, Hartmann OJ, Rubio IT, Santini D, Sardanelli F, Senkus E, van Dam P, Curigliano G, Eusoma Working Group

doi: 10.1016/j.ejca.2026.116259

Breast Cancer

Concurrent Versus Sequential Radiation Dose Escalation to the Surgical Cavity for Conservative Treatment of High-Risk Early Breast Cancer: NRG/RTOG 1005 Phase III Trial

J Clin Oncol

Vicini FA, Winter K, Freedman GM, Arthur DW, Rosenstein BS, Bentzen SM, Li XA, Halyard MY, Woodward WA, Bleicher RJ, Taghian A, Lyons J, Tomberlin JK, Seaward SA, Cheston SB, Hoover AC, Anderson BM, Perera FE, Poppe MM, Petersen IA, Jhawar S, Hijal T, Moughan J, Movsas B, White JR

doi: 10.1200/JCO-25-02465

SPECIAL REPORT

Genitourinary Cancer

Insights from the EMBARK Trial: Identifying Eligible Patients for Optimized Outcomes

Leukemia

Disease risk but not remission status determines transplant outcomes in AML: long-term outcomes of the ASAP trial

Blood

Stelljes M, Middeke JM, Bug G, Wagner-Drouet EM, Mueller LP, Schmid C, Krause SW, Bethge WA, Jost E, Platzbecker U, Klein S, Niederland J, Kaufmann M, Schäfer-Eckart K, Baldauf H, Stölzel F, Trost S, Röllig C, von Bonin M, Egger-Heidrich K, Kunadt D, Steffen B, Hauptrock B, Schliemann C, Sockel K, Lang F, Kriege O, Schaffrath J, Reicherts C, Berdel WE, Serve H, Ehninger G, Schmidt AH, Mikesch JH, Bornhäuser M, Schetelig J

doi: 10.1182/blood.2025028730

Leukemia

Hypertension and time to treatment failure with acalabrutinib and ibrutinib in treatment-naïve CLL/SLL

Leuk Lymphoma

Narkhede MS, Blau S, Peevyhouse A, Neuhalfen H, Dietz LA, Huynh C, Wahlstrom SK, Teschemaker A, Shetty V, Dranitsaris G, Ermann D

doi: 10.1080/10428194.2026.2687635

Related content